XpresCheck® Opens Second COVID-19 Testing Facility at Denver International Airport
XpresSpa Group (Nasdaq: XSPA) has opened its second XpresCheck® COVID-19 testing facility at Denver International Airport (DEN). Located pre-security, the facility features six testing rooms offering a Rapid RT-PCR test and standard PCR test. CEO Scott Milford highlighted the facility's role in enhancing access to reliable COVID-19 testing as international travel resumes. Denver's Senior VP of Concessions stated the importance of rapid testing options for travelers. XpresCheck operates 15 locations in 12 domestic airports as part of XpresSpa's health and wellness portfolio.
- Opening of a second XpresCheck facility at Denver International Airport is expected to increase customer access to COVID-19 testing.
- The facility enhances XpresSpa's reputation as a reliable provider of health services amid increasing demand for COVID-19 testing.
- None.
Located pre-security in the Great Hall
DENVER, Feb. 22, 2022 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced that it has opened a second XpresCheck® COVID-19 testing facility at Denver International Airport (DEN).
XpresCheck is located pre-security in the Great Hall with six separate testing rooms. COVID-19 testing options include a Rapid RT-PCR test and the standard Polymerase Chain Reaction (PCR) Test.
Scott Milford, XpresSpa Group CEO, said, "We are thrilled to open our second testing facility in Denver. This new testing facility is pre-security, so passengers traveling through DEN will now have greater access to testing options so that they can meet the entry requirements of their final destination. The demand for reliable COVID-19 testing remains strong and we are pleased to be providing this additional layer of safety to the traveling public.”
“It is critical for passengers to have an option to get a rapid COVID test pre-security, especially as international travel rebounds,” said DEN Senior Vice President of Concessions Pamela Dechant. “We are excited to bring another COVID testing option to DEN in partnership with XpresSpa.”
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company operating three distinct brands: XpresCheck®, XpresSpa®, Treat™. XpresCheck is a leading on-site airport provider of COVID-19 screening and testing with 15 locations in 12 domestic airports. XpresSpa is a leading airport retailer of spa services and related health and wellness products, with 45 locations in 21 airports globally. Treat is a travel health and wellness brand that is providing on-demand access to healthcare through technology and personalized services. The Company also recently acquired HyperPointe™, a leading digital healthcare and data analytics relationship marketing agency servicing the global healthcare and pharmaceutical industry.
To learn more about XpresSpa Group, visit: www.XpresSpaGroup.com
To learn more about XpresCheck, visit: www.XpresCheck.com
To learn more about XpresSpa, visit: www.XpresSpa.com
To learn more about Treat, visit: www.Treat.com
To learn more about HyperPointe, visit: www.Hyperpointe.com
Twitter: @xprescheck and Instagram: @realxprescheck
Twitter: @XpresSpa and Instagram: @XpresSpa
Twitter: @Treat_Care and Instagram: @treat_care
About Denver International Airport
Denver International Airport is the fifth-busiest airport in the United States, with more than 69 million passengers traveling through the airport in 2019. DEN is the primary economic engine for the state of Colorado, generating more than
Forward-Looking Statements
This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our XpresCheck® concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Investor Relations:
ICR
Raphael Gross
ir@xpresspagroup.com
(203) 682-8253
Media:
Julie Ferguson
Julie@jfprmedia.com
(312) 385-0098
FAQ
What is the significance of XpresSpa opening a second testing facility at Denver International Airport?
What types of COVID-19 tests are available at the new XpresCheck facility?
How many locations does XpresCheck operate now?
Who is the CEO of XpresSpa Group?
